Yes, the primary safety concerns involve the quality of the active ingredient and risk of contamination
According to the company's phase III clinical trial data, patients using oral Wegovy lost approximately 14% of their body weight when combined with reduced-calorie diet and exercise, with those remaining on treatment losing about 17% compared to approximately 3% for placebo recipients
325, 4751.10.1016/S0304-3940(02)00241-0 359 WangT.HungC
However, there is considerable research showing that the bioavailability of peptides and proteins that are taken directly into the gastrointestinal tract is very poor
Introduction Endometrial decidualization is a prerequisite for successful embryo implantation
Individuals with certain medical conditions, a history of specific endocrine disorders, or those who are pregnant or breastfeeding may not be eligible for treatment